-
Dr AI predicts when to stop antidepressants
Monday | Sep 29 2025RESEARCHERS at the University of South Australia (UniSA) have developed new machine learning models to help clinicians identify when patients can successfully stop using long-term antidepressants.
-
Trump pharma tariff announcement creates market jitters
Monday | Sep 29 2025US PRESIDENT Donald Trump announced on social media last Fri that a 100 percent tariff will be imposed on US imports of branded or patented pharmaceutical products from 01 Oct (PD breaking news).
-
Dispensary Corner 29 Sep 25
Monday | Sep 29 2025IT is a well-known fact that having a pet can boost your wellbeing, but as it turns out, owning a dog can reduce the chances of developing childhood asthma.
-
PD for Mon 29 Sep 2025
Monday | Sep 29 2025GPs urge govt to fund multidisciplinary care model, encouraging trends around naloxone reported, Pharmx addresses ordering pain point, and more
-
PD breaking news – Trump announces 100% tariff on pharma imports
Friday | Sep 26 2025A 100 percent tariff will be imposed on US imports of branded or patented pharmaceutical products…
-
Wesfarmers moves into menopause
Friday | Sep 26 2025PRICELINE Pharmacy has launched Anything Menopause, an initiative designed to provide women with accessible, informed advice and care around menopause in stores throughout the country.
-
“Sustained investment needed”
Friday | Sep 26 2025ON WORLD Pharmacists Day yesterday, Advanced Pharmacy Australia (AdPha) celebrated the evolving role of pharmacists to ensure safe, cost-effective and accessible care, while calling for sustained investment in the hospital pharmacy workforce.
-
Expanded pharmacist care for Tasmania
Friday | Sep 26 2025THE Tasmanian Government announced yesterday it will expand the role of community pharmacists, enabling them to provide more accessible care, as promised prior to the election in Jul (PD 17 Jun).
-
Leqembi approved for early Alzheimer’s
Friday | Sep 26 2025THE Therapeutic Goods Administration (TGA) has approved the registration of Leqembi (lecanemab) for use as an amyloid-lowering therapy in adult patients for the treatment of mild cognitive impairment due to Alzheimer’s disease and early Alzheimer’s disease that are apolipoprotein E 4 (APOE4) non-carriers or heterozygotes.
-
All treats, no tricks
Friday | Sep 26 2025CUSTOMERS have a chance to win the ultimate Halloween treat haul – a year’s supply of Glucojel products.
PARTNER SITES
to top